Two Lesser-Known Cannabinoids Reduced Pain Through Multiple Receptor Pathways

Both CBV and THCV produced dose-dependent antinociceptive effects in C. elegans thermotaxis assays. Experiments with mutant worm strains showed the pain-relieving effects were mediated through vanilloid receptor homologs (OCR-2, OSM-9) and cannabinoid receptor homologs (NPR-19, NPR-32). Proteomics identified the biological pathways involved.

Thermotaxis assays in wild-type and mutant C. elegans strains (deficient in vanilloid and cannabinoid receptor homologs) to establish dose-response relationships and identify molecular targets. Mass spectrometry proteomics combined with network biology analysis.

CBV and THCV are non-psychoactive cannabinoids that have received far less research attention than CBD and THC. Demonstrating their analgesic mechanisms through conserved receptor pathways supports further investigation in mammalian pain models.

The cannabis plant contains over 100 cannabinoids, most of which are poorly studied. Finding that minor cannabinoids like CBV and THCV have pain-relieving properties through identified receptor pathways expands the potential pharmacological toolkit beyond CBD and THC.

C. elegans is a nematode worm, and while receptor homologs are conserved, translating findings to mammalian or human pain is highly uncertain. The study establishes mechanism but cannot predict therapeutic efficacy in humans.